Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year Net income of $1.8 million, an increase of 162% Adjusted EBITDA (non-GAAP) margin expanded by 2.8% to 22% Reaffirms Full-Year 2024 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2024. 2024 Third Quarter Overview: Net revenues totaled $35.3 million, an increase of 11% vs. prior year. Patient Services net revenue was $20.8 million, an increase of 8% vs

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, November 7, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th

Record Net Revenues of $33.7 million Representing 6% Growth from the Prior Year Reaffirms Full-Year 2024 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2024. 2024 Second Quarter Overview: Net revenues totaled $33.7 million, an increase of 6% vs. prior year. Patient Services net revenue was $20.2 million, an increase of 5% vs. prior year. Device Solutions net revenue was $13.5 million, an increase of 8% vs. prior year. Gros

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, August 8, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th

Record Net Revenues of $32.0 million Representing 5% Growth from the Prior Year Gross Profit increased 10% - Gross Margin of 51.5%, an increase of 2.3% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2024. 2024 First Quarter Overview: Net revenues totaled $32.0 million, an increase of 5% vs. prior year. Patient Services net revenue was $18.6 million, a decrease of 1% vs. prior year. Device Solutions net revenue was $13.4 million, an incre

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue first quarter 2024 financial results on Thursday, May 9, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, May 9, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (800) 285-6670 or (713) 481-1320, or listen via a live webcast, which is available in the Inves

Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $49.2 million, increases of 11% and 20% Adjusted EBITDA (non-GAAP): $22.4 million, an 8% increase Five Year CAGR: Net Revenues 13% and Adjusted EBITDA 10% InfuSystem Holdings, Inc. (NYSE:INFU), ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Overview: Net revenues totaled $31.8 million, an

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue preliminary fourth quarter and full year 2023 financial results on Thursday, March 14, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, March 14, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast

Record Net Revenues of $31.9 million Representing 17% Growth from the Prior Year Operating Income Increased 80% - Net Income Increased 56% - Adjusted EBITDA Increased 11% Raising Full Year 2023 Net Revenue Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2023. 2023 Third Quarter Overview: Net revenues totaled $31.9 million, an increase of 17% vs. prior year. Patient Services (formerly Integrated Therapy Services ("ITS")) net re

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2023 financial results on Tuesday, November 7, 2023, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, November 7, 2023 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in t

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year Net income of $1.8 million, an increase of 162% Adjusted EBITDA (non-GAAP) margin expanded by 2.8% to 22% Reaffirms Full-Year 2024 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2024. 2024 Third Quarter Overview: Net revenues totaled $35.3 million, an increase of 11% vs. prior year. Patient Services net revenue was $20.8 million, an increase of 8% vs

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, November 7, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th

Fireside Chat to be held at 3:30pm ET InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Carrie Lachance, President and Chief Operating Officer and Barry Steele, Chief Financial Officer will participate in the Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024. The webcasted fireside chat with CEO, Richard DiIorio will take place at 3:30pm ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, and its joint venture partner Sanara MedTech Inc. ("Sanara"), announced today the execution of an exclusive United States distribution agreement with ChemoMouthpiece, LLC ("ChemoMouthpiece"). Richard DiIorio, InfuSystem's CEO, stated, "Sanara and InfuSystem entered into our partnership in order to bring together our combined technical, operational and commercial strengths to deliver proprietary efficacious products to patients. We believe this exclusive agreement, which bui

FORT WORTH, TX, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets, and InfuSystem, Inc. ("InfuSystem"), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, Inc., announced today the execution of an exclusive United States distribution agreement with, and minority investment in, ChemoMouthpiece, LLC ("ChemoMouthpiece"). Ron Nixon, Sanara's CEO, stated, "Oral mucositis is a debilitating conditi

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer will participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference on Thursday, September 12, 2024. The conference is being held at The Yale Club in New York City. Management will be available for one-on-one and group meetings with investors throughout the day. To receive additional information, request an invitation or to schedule a one-on-o

Record Net Revenues of $33.7 million Representing 6% Growth from the Prior Year Reaffirms Full-Year 2024 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2024. 2024 Second Quarter Overview: Net revenues totaled $33.7 million, an increase of 6% vs. prior year. Patient Services net revenue was $20.2 million, an increase of 5% vs. prior year. Device Solutions net revenue was $13.5 million, an increase of 8% vs. prior year. Gros

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today a three-year distribution agreement with Smith+Nephew for its innovative negative pressure wound therapy ("NPWT") system and supplies. Under this agreement, InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE negative pressure wound therapy system, an exciting new option in home-based care for patients living with chronic wounds. The RENASYS EDGE system is lightweight and compact allowing it to be easily carried or worn, featuring a discreet caniste

Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, August 8, 2024 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in th

B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00

Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00

SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G/A - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G - InfuSystem Holdings, Inc (0001337013) (Subject)

SC 13G/A - InfuSystem Holdings, Inc (0001337013) (Subject)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has

ROCHESTER HILLS, Michigan, March 02, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Carrie Lachance has been appointed as President in addition to her current role as Chief Operating Officer. Richard DiIorio, chief executive officer of InfuSystem said, “I am pleased to announce the promotion of Carrie Lachance to President of InfuSystem. Carrie has achieved outstanding results exhibiting solid leadership in her role as Chief Operating Officer in managing patient a

InfuSystems Holdings (AMEX:INFU) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $31.995 million which missed the analyst consensus estimate of $32.000 million by 0.02 percent. This is a 5.35 percent increase over sales of $30.370 million the same period last year.

The company intends to regain compliance with the Exchange's continued listing standards. There can be no assurance that the company will ultimately regain compliance with all applicable Exchange listing standards.

InfuSystems Holdings (AMEX:INFU) reported quarterly sales of $31.77 million which beat the analyst consensus estimate of $30.00 million by 5.90 percent. This is a 10.20 percent increase over sales of $28.83 million the same period last year.

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. • ImmunoPrecise Antibodies (NASDAQ:IPA) is likely to report quarterly loss at $0.07 per share on revenue of $4.50 million. • G-III Apparel Group (NASDAQ:GIII) is projected to report quarterly earnings at $0.67 per share on revenue of $817.48 million. • Dick's Sporting Goods (NYSE:DKS) is estimated to report quarterly earnings at $3.35 per share on revenue of $3.80 billion. • Protalix BioTherapeutics (AMEX:PLX) is likely to report quarterly loss at $0.03 per share on revenue of $5.80 million. • Hello Gr (NASDAQ:MOMO) is likely to report quarterly earnings at $0.34 per sha

InfuSystems Holdings (AMEX:INFU) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement. Analysts estimate that InfuSystems Holdings will report an earnings per share (EPS) of $0.00. InfuSystems Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.01, which was followed by a

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. • Ballard Power Systems (NASDAQ:BLDP) is expected to report quarterly loss at $0.13 per share on revenue of $26.20 million. • Melco Resorts and Enter (NASDAQ:MLCO) is likely to report quarterly earnings at $0.03 per share on revenue of $1.03 billion. • Consolidated Comms Hldgs (NASDAQ:CNSL) is expected to report quarterly loss at $0.37 per share on revenue of $274.23 million. • Sophia Genetics (NASDAQ:SOPH) is projected to report quarterly loss at $0.31 per share on revenue of $15.63 million. • Endeavor Gr Hldgs (NYSE:EDR) is estimated to report quarterly earnings